MedMira Headquarters Visited by China's State Food and Drug Administration Only Canadian Company to Receive State Agency Visit HALIFAX, April 21 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that two directors from China's State Food and Drug Administration (SFDA) recently visited MedMira's corporate offices and manufacturing facilities in Halifax, Nova Scotia. The directors were part of an eight-member delegation from the SFDA, invited by the United States and Canadian regulatory bodies. The SFDA is the state authority in China governing all drug and medical devices manufactured by both domestic and foreign companies. The Biological Division of the SFDA is responsible for review and approval of HIV testing devices, such as MedMira's currently approved MiraWell(TM) Rapid HIV Test and the new rapid fingerstick whole blood test, which is undergoing clinical trials in China. MedMira is the only Canadian company currently licensed to import rapid HIV tests into China. "We were pleased to visit MedMira and observe their high-quality manufacturing facilities," said Dr. Yin Hongjhang, Director of the Biological Division of the SFDA during his speech at a dinner reception. "We are thrilled to have gained the opportunity to view, first-hand, the upcoming products for which MedMira plans to seek our approval." Dr. Chang Yongheng, Director of the Product Registration Division of the SFDA, also presented an updated SFDA approval algorithm for new medical devices at the reception. "We greatly welcomed this visit from the SFDA delegates in our Halifax facilities, and are extremely thankful to representatives from our federal and provincial governments and business community who joined us to greet our guests," said Stephen Sham, Chairman and CEO of MedMira. "As we continue to increase our product portfolio in the China market, we are delighted to see the interest from these two directors in our newest innovations." MedMira's MiraWell(TM) Rapid HIV test is currently used by public health organizations in China's Jilin province, a result of the first provincial government tender to be awarded to a Canadian company. It was recently ranked the number one rapid HIV test in overall performance in a 2004 China National Center for Disease Control (CDC) report. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow-through rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter (OTC) in pharmacies throughout the Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail:

Copyright